Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Large Growth in Short Interest

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 10,189 shares, a growth of 67.9% from the May 14th total of 6,068 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 7,808 shares, the short-interest ratio is currently 1.3 days.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Molecular Partners Stock Performance

MOLN stock traded up $0.03 during mid-day trading on Wednesday, hitting $3.95. The company had a trading volume of 2,587 shares, compared to its average volume of 4,712. The firm has a market cap of $159.58 million, a PE ratio of -2.04 and a beta of 1.07. Molecular Partners has a 12 month low of $3.41 and a 12 month high of $5.36. The stock’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $4.31.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). Equities analysts anticipate that Molecular Partners will post -1.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Molecular Partners in a research note on Wednesday, April 22nd. TD Cowen restated a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Molecular Partners currently has a consensus rating of “Hold” and an average price target of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.